Northrop Grumman: Immunity From The Coronavirus With A Lower Valuation

The recent dip in Northrop's stock may create a good buying opportunity from a long-term investing perspective. Northrop's backlog increase provides a catalyst for revenue growth. Multiple-year double-digit earnings growth can help drive the stock for above-average gains.

Most of the defense-related companies have a positive future outlook. This is a result of the steady expected annual growth of about 3% through 2023 for U.S. defense spending. The company that I'm focusing on in this article is the global security firm Northrop Grumman (NOC).

Northrop looks like a solid investment due to its backlog growth of 21% in 2019 over the prior year. Bookings increased at a strong pace at 66% over the same time period. Northrop tends to be awarded lucrative contracts on an ongoing basis, which drives this growth, leading to revenue and earnings increases.

CLICK LINK TO READ ENTIRE ARTICLE: https://seekingalpha.com/article/4333727-northrop-grumman-immunity-from-coronavirus-lower-valuation

Disclaimer: This and other personal blog posts are not reviewed, monitored or endorsed by TalkMarkets. The content is solely the view of the author and TalkMarkets is not responsible for the content of this post in any way. Our curated content which is handpicked by our editorial team may be viewed here.

STOCKS IN THIS BLOG POST

Comments